The clinical management of non-alcoholic steatohepatitis (NASH) has undergone revolutionary transformation with the introduction of Rezdiffra (resmetirom) by Madrigal Pharmaceuticals, creating an unprecedented milestone in specialized liver therapeutics. This innovative pharmaceutical achievement represents the first regulatory-approved medication specifically engineered to treat NASH...
العربية
Français
Español
Português
Deutsch
Türkçe
Nederlands
Italiano
Русский
Română
Português
Ελληνικά
Tiếng Việt